Factores clínicos asociados a la retinopatía del prematuro en neonatos tamizados con inteligencia artificial mediante VART Y RETCAM en una clínica de Barranquilla (2023–2024)

datacite.rightshttp://purl.org/coar/access_right/c_f1cf
dc.contributor.advisorPiñeros, Hildegard
dc.contributor.advisorPolo Gallardo, Raúl
dc.contributor.authorEstupiñán Bucheli, María Isabel
dc.contributor.authorQuintero Arciniegas, Laura
dc.date.accessioned2025-07-03T19:30:19Z
dc.date.available2025-07-03T19:30:19Z
dc.date.issued2025
dc.description.abstractIntroducción: La retinopatía del prematuro ( ROP) es una de las principales causas de ceguera infantil prevenible, especialmente en países en desarrollo. En Barranquilla, donde la atención neonatal ha mejorado, persiste la necesidad de actualizar los datos sobre su incidencia, como también sobre las herramientas diagnósticas y terapéuticas más utilizadas. En este contexto, la inteligencia artificial (IA) se ha propuesto como una alternativa para mejorar el tamizaje oportuno y reducir la carga sobre el especialista. Objetivo: Determinar los factores clínicos asociados a la presencia y severidad de la retinopatía del prematuro en neonatos tamizados con inteligencia artificial mediante VART y RetCam en una clínica de Barranquilla durante el periodo 2023–2024. Materiales y métodos: Estudio observacional, transversal retrospectivo, con enfoque analítico, realizado entre enero de 2023 y diciembre de 2024. Se incluyeron 596 ojos de recién nacidos prematuros tamizados mediante el sistema RetCam y evaluados con inteligencia artificial (VART) en siete UCIN de Barranquilla. Se aplicaron análisis estadísticos descriptivos, pruebas inferenciales y regresión logística para identificar los factores asociados a la ROP. Resultados: La prevalencia de ROP fue del 19.5%. La edad gestacional promedio fue de 28.6 semanas y el peso al nacer de 1263.7 g. Se encontró una asociación significativa entre menor edad gestacional y bajo peso con la aparición de ROP (p<0.001). El 84.4% de los casos con ROP recibió tratamiento, siendo el láser la modalidad más utilizada (64.2 %), seguido de combinaciones con Anti-VEGF (26.5%). La IA empleada en el sistema VART demostró una sensibilidad del 80% para el tamizaje de ROP.spa
dc.description.abstractIntroduction: Retinopathy of prematurity (ROP) is one of the leading causes of preventable childhood blindness, particularly in developing countries. In Barranquilla, where neonatal care has improved, there remains a need to update data on its incidence, as well as on the most commonly used diagnostic and therapeutic tools. In this context, artificial intelligence (AI) has been proposed as an alternative to improve timely screening and reduce the burden on specialists. Objective: To determine the clinical factors associated with the presence and severity of retinopathy of prematurity in neonates screened with artificial intelligence using VART and RetCam at a clinic in Barranquilla during the 2023–2024 period. Materials and Methods: Observational, cross-sectional, and retrospective study with an analytical approach, conducted between January 2023 and December 2024. A total of 596 eyes of premature newborns screened using the RetCam system and evaluated with artificial intelligence (VART) in seven NICUs in Barranquilla were included. Descriptive statistical analyses, inferential tests, and logistic regression were applied to identify factors associated with ROP. Results: The prevalence of ROP was 19.5%. The mean gestational age was 28.6 weeks, and the average birth weight was 1263.7 g. A significant association was found between lower gestational age and birth weight with the development of ROP (p < 0.001). Of the cases with ROP, 84.4% received treatment, with laser being the most commonly used modality (64.2%), followed by combinations with anti-VEGF (26.5%). AI used in the VART system demonstrated a sensitivity of 80% for ROP screening.eng
dc.format.mimetypepdf
dc.identifier.urihttps://hdl.handle.net/20.500.12442/16795
dc.language.isospa
dc.publisherEdiciones Universidad Simón Bolívarspa
dc.publisherFacultad de Ciencias de la Saludspa
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internationaleng
dc.rights.accessrightsinfo:eu-repo/semantics/embargoedAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectRetinopatía del prematurospa
dc.subjectPrematuridadspa
dc.subjectInteligencia artificialspa
dc.subjectScreening neonatalspa
dc.subjectFactores de riesgospa
dc.subjectAnti-VEGFspa
dc.subjectFotocoagulación láserspa
dc.subject.keywordsRetinopathy of prematurityeng
dc.subject.keywordsPrematurityeng
dc.subject.keywordsArtificial Intelligenceeng
dc.subject.keywordsNeonatal screeningeng
dc.subject.keywordsRisk factorseng
dc.subject.keywordsLaser photocoagulationeng
dc.titleFactores clínicos asociados a la retinopatía del prematuro en neonatos tamizados con inteligencia artificial mediante VART Y RETCAM en una clínica de Barranquilla (2023–2024)spa
dc.type.driverinfo:eu-repo/semantics/other
dc.type.spaOtros
dcterms.referencesRaghuveer TS, Zackula R. Strategies to Prevent Severe Retinopathy of Prematurity: A 2020 Update and Meta-analysis. NeoReviews. 2020;21(4): e249–63. doi: 10.1542/neo.21-4-e249.ProlactaBioScience+1Frontiers+1eng
dcterms.referencesTarnow-Mordi W, Kirby A. Current Recommendations and Practice of Oxygen Therapy in Preterm Infants. Clin Perinatol. 2019 Sep;46(3):621–36. doi: 10.1016/j.clp.2019.05.015.eng
dcterms.referencesBujoreanu Bezman L, Tiutiuca C, Totolici G, Carneciu N, Bujoreanu FC, Ciortea DA, et al. Latest Trends in Retinopathy of Prematurity: Research on Risk Factors, Diagnostic Methods and Therapies. Int J Gen Med. 2023; 16:937–49. doi: 10.2147/IJGM.S405179.eng
dcterms.referencesZhu T, Zhang L, Zhao F, Qu Y, Mu D. Association of maternal hypertensive disorders with retinopathy of prematurity: A systematic review and meta-analysis. PLoS One. 2017 Apr 7;12(4): e0175374. doi: 10.1371/journal.pone.0175374.eng
dcterms.referencesTunay ZÖ, Özdemir Ö, Acar DE, Öztuna D, Uraş N. Maternal Diabetes as an Independent Risk Factor for Retinopathy of Prematurity in Infants With Birth Weight of 1500 g or More. Am J Ophthalmol. 2016 Aug; 168:201–6. doi: 10.1016/j.ajo.2016.05.006.eng
dcterms.referencesOrganización Panamericana de la Salud. Síntesis de evidencia y recomendaciones: guía de práctica clínica para el manejo de la retinopatía de la prematuridad. Rev Panam Salud Pública. 2021 Dec 22; 45:1.spa
dcterms.referencesPontificia Universidad Javeriana. Guía de atención integral del recién nacido prematuro [Internet]. 2012 [cited 2025 May]. Available from: https://scp.com.co/wp content/uploads/2014/08/3_GAI.pspa
dcterms.referencesGiraldo Restrepo MM, Hurtado Guzmán A, Donado Gómez JH, Molina Betancur MC. Epidemiología de la retinopatía del prematuro en Medellín, 2003–2008. Iatreia [Internet]. 2012 Feb 6 [cited 2025 Jan 2];24(3). Available from: https://revistas.udea.edu.co/index.php/iatreia/article/view/10545spa
dcterms.referencesAbdala Caballero C, Acosta Reyes J, Izquierdo León MA. Caracterización de la retinopatía de la prematuridad entre el período de 2008 y 2014 en Barranquilla, Colombia. Rev Cienc Salud. 2015;3(48):213–22.spa
dcterms.referencesEsmeral D. Incidencia de la retinopatía de la prematuridad y factores neonatales asociados en el Área Metropolitana de Bucaramanga [Internet]. 2023 [cited 2025 May]. Available from: http://hdl.handle.net/20.500.12749/21288spa
dcterms.referencesBrown AC, Nwanyanwu K. Retinopathy of prematurity. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan– [updated 2023 Sep 4]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK562319/eng
dcterms.referencesMinisterio de Salud y Protección Social, Colciencias. Guía de práctica clínica del recién nacido prematuro. Guía No. 04. Bogotá, Colombia: Ministerio de Salud; 2013.spa
dcterms.referencesConsejo Privado de Competitividad. Algunos desafíos del sistema de salud en Colombia [Internet]. 2025 [cited 2025 May]. Available from: https://compite.com.co/blog_cpc/algunos-desafios-del-sistema-de-salud-en colombiaspa
dcterms.referencesGensure RH, Chiang MF, Campbell JP. Artificial intelligence for retinopathy of prematurity. Curr Opin Ophthalmol. 2020 Sep;31(5):312–7. doi:10.1097/ICU.0000000000000683eng
dcterms.referencesRallis D, Baltogianni M, Kapetaniou K, Giapros V. Current applications of artificial intelligence in the neonatal intensive care unit. BioMedInformatics. 2024 May 9;4(2):1225–48. doi:10.3390/biomedinformatics4020015eng
dcterms.referencesHong EH, Shin YU, Cho H. Retinopathy of prematurity: a review of epidemiology and current treatment strategies. Clin Exp Pediatr. 2022 Mar 15;65(3):115–26. doi:10.3345/cep.2021.00897eng
dcterms.referencesDammann O, Hartnett ME, Stahl A. Retinopathy of prematurity. Dev Med Child Neurol. 2023 May;65(5):625–31. doi:10.1111/dmcn.15255eng
dcterms.referencesRivera JC, Sapieha P, Joyal JS, Duhamel F, Shao Z, Sitaras N, et al. Understanding retinopathy of prematurity: update on pathogenesis. Neonatology. 2011;100(4):343– 53. doi:10.1159/000330628eng
dcterms.referencesOrganización Panamericana de la Salud. Guía de práctica clínica para el manejo de la retinopatía de la prematuridad. Washington, D.C.: OPS; 2018.spa
dcterms.referencesKim SJ, Port AD, Swan R, Campbell JP, Chan RVP, Chiang MF. Retinopathy of prematurity: a review of risk factors and their clinical significance. Surv Ophthalmol. 2018 Sep;63(5):618–37. doi:10.1016/j.survophthal.2018.03.006eng
dcterms.referencesRaghuveer TS, Zackula R. Strategies to prevent severe retinopathy of prematurity: a 2020 update and meta-analysis. NeoReviews. 2020 Apr;21(4):e249–63. doi:10.1542/neo.21-4-e249eng
dcterms.referencesTarnow-Mordi W, Kirby A. Current recommendations and practice of oxygen therapy in preterm infants. Clin Perinatol. 2019 Sep;46(3):621–36. doi:10.1016/j.clp.2019.05.003eng
dcterms.referencesBujoreanu Bezman L, Tiutiuca C, Totolici G, Carneciu N, Bujoreanu FC, Ciortea DA, et al. Latest trends in retinopathy of prematurity: research on risk factors, diagnostic methods and therapies. Int J Gen Med. 2023 Mar;16:937–49. doi:10.2147/IJGM.S390471eng
dcterms.referencesZhu T, Zhang L, Zhao F, Qu Y, Mu D. Association of maternal hypertensive disorders with retinopathy of prematurity: a systematic review and meta-analysis. PLoS One. 2017 Apr 7;12(4):e0175374. doi:10.1371/journal.pone.0175374eng
dcterms.referencesTunay ZÖ, Özdemir Ö, Acar DE, Öztuna D, Uraş N. Maternal diabetes as an independent risk factor for retinopathy of prematurity in infants with birth weight of 1500 g or more. Am J Ophthalmol. 2016 Aug;168:201–6. doi:10.1016/j.ajo.2016.05.027eng
dcterms.referencesWu WC, Ong FSC, Kuo JZC, Lai CC, Wang NC, Chen KJ, et al. Retinopathy of prematurity and maternal age. Retina. 2010 Feb;30(2):327–31. doi:10.1097/IAE.0b013e3181b5a0f8eng
dcterms.referencesSchmidl D, Schmetterer L, Garhöfer G, Popa-Cherecheanu A. Gender differences in ocular blood flow. Curr Eye Res. 2015 Feb;40(2):201–12. doi:10.3109/02713683.2014.916020eng
dcterms.referencesDogra MR, Katoch D, Dogra M. An update on retinopathy of prematurity (ROP). Indian J Pediatr. 2017 Dec;84(12):930–6. doi:10.1007/s12098-017-2439-1eng
dcterms.referencesPalmer EA. Results of U.S. randomized clinical trial of cryotherapy for ROP (CRYO ROP). Doc Ophthalmol. 1990 Mar;74(3):245–51. doi:10.100eng
dcterms.referencesChiang MF, Quinn GE, Fielder AR, Ostmo SR, Chan RVP, Berrocal A, et al. International classification of retinopathy of prematurity, third edition. Ophthalmology. 2021 Oct;128(10):e51–68. doi:10.1016/j.ophtha.2021.05.02eng
dcterms.referencesBancalari MA, Schade R. Retinopatía del prematuro: actualización en detección y tratamiento. Rev Chil Pediatr. 2020 Feb;91(1):122.spa
dcterms.referencesReynolds JD. Evidence-based screening criteria for retinopathy of prematurity: natural history data from the CRYO-ROP and LIGHT-ROP studies. Arch Ophthalmol. 2002 Nov;120(11):1470. doi:10.1001/archopht.120.11.1470eng
dcterms.referencesFierson WM; American Academy of Pediatrics Section on Ophthalmology; American Academy of Ophthalmology; American Association for Pediatric Ophthalmology and Strabismus; American Association of Certified Orthoptists; Chiang MF, et al. Screening examination of premature infants for retinopathy of prematurity. Pediatrics. 2018 Dec;142(6):e20183061. doi:10.1542/peds.2018-3061eng
dcterms.referencesTing DSW, Pasquale LR, Peng L, Campbell JP, Lee AY, Raman R, et al. Artificial intelligence and deep learning in ophthalmology. Br J Ophthalmol. 2019 Feb;103(2):167–75. doi:10.1136/bjophthalmol-2018-313173eng
dcterms.referencesBrady CJ, D’Amico S, Campbell JP. Telemedicine for retinopathy of prematurity. Telemed J E Health. 2020 Apr;26(4):556–64. doi:10.1089/tmj.2019.0144eng
dcterms.referencesDaich Varela M, Sen S, De Guimaraes TAC, Kabiri N, Pontikos N, Balaskas K, et al. Artificial intelligence in retinal disease: clinical application, challenges, and future directions. Graefes Arch Clin Exp Ophthalmol. 2023 Nov;261(11):3283–97. doi:10.1007/s00417-023-06141-7eng
dcterms.referencesEarly Treatment For Retinopathy of Prematurity Cooperative Group. Multicenter trial of early treatment for retinopathy of prematurity: study design. Control Clin Trials. 2004 Jun;25(3):311–25. doi:10.1016/j.cct.2004.04.003eng
dcterms.referencesSen P, Wu WC, Chandra P, Vinekar A, Manchegowda PT, Bhende P. Retinopathy of prematurity treatment: Asian perspectives. Eye (Lond). 2020 Apr;34(4):632–42. doi:10.1038/s41433-019-0714-8eng
dcterms.referencesKhokhar S, Surve A, Verma S, Azad S, Chandra P, Dhull C, et al. Cataract in retinopathy of prematurity – a review. Indian J Ophthalmol. 2022 Feb;70(2):369–77. doi:10.4103/ijo.IJO_1465_21eng
dcterms.referencesGeloneck MM, Chuang AZ, Clark WL, Hunt MG, Norman AA, Packwood EA, et al. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol. 2014 Nov;132(11):1327. doi:10.1001/jamaophthalmol.2014.1960eng
dcterms.referencesMintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011 Feb 17;364(7):603–15. doi:10.1056/NEJMoa1007374eng
dcterms.referencesWallace DK, Dean TW, Hartnett ME, Kong L, Smith LE, Hubbard GB, et al. A dosing study of bevacizumab for retinopathy of prematurity. Ophthalmology. 2018 Dec;125(12):1961–6. doi:10.1016/j.ophtha.2018.06.020eng
dcterms.referencesStahl A, Lepore D, Fielder A, Fleck B, Reynolds JD, Chiang MF, et al. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. Lancet. 2019 Oct;394(10208):1551–9. doi:10.1016/S0140-6736(19)32460-9eng
dcterms.referencesMarlow N, Stahl A, Lepore D, Fielder A, Reynolds JD, Zhu Q, et al. 2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open-label, randomised controlled trial. Lancet Child Adolesc Health. 2021 Oct;5(10):698–707. doi:10.1016/S2352-4642(21)00192-4eng
dcterms.referencesStahl A, Sukgen EA, Wu WC, Lepore D, Nakanishi H, Mazela J, et al. Effect of intravitreal aflibercept vs laser photocoagulation on treatment success of retinopathy of prematurity: the FIREFLEYE randomized clinical trial. JAMA. 2022 Jul 26;328(4):348–57. doi:10.1001/jama.2022.10743eng
dcterms.referencesStahl A, Nakanishi H, Lepore D, Wu WC, Azuma N, Jacas C, et al. Intravitreal aflibercept vs laser therapy for retinopathy of prematurity: two-year efficacy and safety outcomes in the nonrandomized controlled trial FIREFLEYE next. JAMA Netw Open. 2024 Apr 30;7(4):e248383. doi:10.1001/jamanetworkopen.2024.8383eng
dcterms.referencesCusick M, Charles MK, Agrón E, Sangiovanni JP, Ferris FL, Charles S. Anatomical and visual results of vitreoretinal surgery for stage 5 retinopathy of prematurity. Retina. 2006 Sep;26(7):729–35. doi:10.1097/01.iae.0000222578.75856.a9eng
dcterms.referencesMintz-Hittner HA, O’Malley RE, Kretzer FL. Long-term form identification vision after early, closed, lensectomy-vitrectomy for stage 5 retinopathy of prematurity. Ophthalmology. 1997 Mar;104(3):454–9. doi:10.1016/S0161-6420(97)30103-9eng
dcterms.referencesBhavsar AR, editor. Operative techniques in vitreoretinal surgery. Philadelphia, PA: Elsevier; 2023. 320 p.eng
dcterms.referencesRivera JC, Duchemin-Kermorvant E, Dorfman A, Zhou TE, Ospina LH, Chemtob S. Retinopathy of prematurity. In: Buonocore G, Bracci R, Weindling M, editors. Neonatology [Internet]. Cham: Springer International Publishing; 2018 [cited 2025 May 16]. p. 1–39. Available from: http://link.springer.com/10.1007/978-3-319-18159- 2_283-2eng
dcterms.referencesLakhanpal RR, Sun RL, Albini TA, Holz ER. Tasa de éxito anatómico tras vitrectomía con preservación del cristalino de 3 puertos en la retinopatía del prematuro en estadio 4A o 4B. Ophthalmology. 2005;112:1569–73.spa
dcterms.referencesBarnett JM, Hubbard GB. Complications of retinopathy of prematurity treatment. Curr Opin Ophthalmol. 2021 Sep;32(5):475–81. doi:10.1097/ICU.0000000000000768eng
dcterms.referencesEarly Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003 Dec 1;121(12):1684–94. doi:10.1001/archopht.121.12.1684eng
dcterms.referencesQuinn GE, Dobson V, Repka MX, Reynolds J, Kivlin J, Davis B, et al. Development of myopia in infants with birth weights less than 1251 grams. Ophthalmology. 1992 Mar;99(3):329–40. doi:10.1016/S0161-6420(92)31501-9eng
dcterms.referencesRayess N, Rahimy E, Storey P, Shah CP, Wolfe JD, Chen E, et al. Postinjection endophthalmitis rates and characteristics following intravitreal bevacizumab, ranibizumab, and aflibercept. Am J Ophthalmol. 2016 May;165:88–93. doi:10.1016/j.ajo.2016.01.022eng
dcterms.referencesChandra P, Kumawat D, Tewari R, Azimeera S. Post-Ranibizumab injection endophthalmitis in aggressive posterior retinopathy of prematurity. Indian J Ophthalmol. 2019;67(6):967–9. doi:10.4103/ijo.IJO_2163_18eng
dcterms.referencesThordsen JE, Harris L, Hubbard GB. Pediatric endophthalmitis: a 10-year consecutive series. Retina. 2008 Mar;28(3):S3–7. doi:10.1097/IAE.0b013e318160e98eeng
dcterms.referencesPaysse E. Acquired cataracts after diode laser photocoagulation for threshold retinopathy of prematurity. Ophthalmology. 2002 Sep;109(9):1662–5. doi:10.1016/S0161-6420(02)01114-2eng
dcterms.referencesCryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity: preliminary results. Arch Ophthalmol. 1988 Apr 1;106(4):471–9. doi:10.1001/archopht.1988.01060160075036eng
oaire.versioninfo:eu-repo/semantics/acceptedVersion
sb.programaEspecialización en Oftalmologíaspa
sb.sedeSede Barranquillaspa

Archivos

Bloque original
Mostrando 1 - 2 de 2
No hay miniatura disponible
Nombre:
PDF_Resumen.pdf
Tamaño:
264.15 KB
Formato:
Adobe Portable Document Format
No hay miniatura disponible
Nombre:
PDF.pdf
Tamaño:
1.06 MB
Formato:
Adobe Portable Document Format
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
2.93 KB
Formato:
Item-specific license agreed upon to submission
Descripción:

Colecciones